chloroquine - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.37 [0.73, 2.56]> 10%1 study (1/-)83.8 %NAnot evaluable important-
clinical improvement (14-day) 1.37 [0.73, 2.56]> 10%1 study (1/-)83.8 %NAnot evaluable important-
hospital discharge 2.00 [1.15, 3.47]> 10%1 study (1/-)99.3 %NAnot evaluable important-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %NAnot evaluable important-
radiologic improvement (7-day) 2.40 [0.26, 22.51]> 10%1 study (1/-)77.7 %NAnot evaluable important-
viral clearance 1.20 [0.78, 1.85]> 10%1 study (1/-)79.5 %NAnot evaluable important-
viral clearance by day 14 1.09 [0.95, 1.26]> 10%1 study (1/-)88.2 %NAnot evaluable important-
viral clearance by day 7 1.20 [0.60, 2.40]> 10%1 study (1/-)69.7 %NAnot evaluable important-

safety endpoints 00

adverse events 1.80 [0.14, 23.37]< 10%1 study (1/-)32.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.